Tasly will gain rights for Exebryl-1 for China, and ProteoTech will retain rights for the U.S

If approved in the U.S., Eisai will hold marketing rights in the U.S

Partnership to distribute Prestige Antibodies, which were developed by the Human Proteome Resource, to the proteomics and cell biology research communities Sigma-Aldrich gets exclusive distribution rights in the U.S

I. MODIFIED AGREEMENTS Company* (Country; Symbol) Company* (Country; Symbol) Change from original agreement Terms/Details (Date) FIRST QUARTER Alimera Sciences Inc.* pSivida Ltd. (PSDV) Amended license and collaboration agreement relating to Medidur FA for diabetic macular edema, and other Medidur products Alimera is increasing its equity in the future profits of Medidur FA from 50% to 80%, in exchange for consideration of up to about $78M to pSivida, including $12M up front (3/17

Deal to develop and market Posidur The companies will jointly fund remaining development costs, and Hospira holds commercialization rights in the U.S

Deal to develop and market Posidur The companies will jointly fund remaining development costs, and Hospira holds commercialization rights in the U.S

Tranzyme retains development rights in the U.S

While Hospira holds exclusive Posidur commercialization rights in the U.S

rights in the U.S

Alnylam has retained certain product opt-in rights in the U.S

ZymoGenetics regains full promotion rights in the U.S

Biotech Co.* (Country; Symbol) Pharma Co. (Country) Product Terms/Details (Date) FIRST QUARTER Acambis plc (UK; LSE:ACM) Sanofi Pasteur (France) Agreement to license a single dose vaccine, ChimeriVax, for Japanese encephalitis Deal could be worth nearly $40M; Sanofi Pasteur gains marketing, distribution and certain manufacturing rights worldwide, excluding India and the Indian subcontinent, and the U.S., for which Sanofi Pasteur has an option (2/14) Affectis Pharmaceuticals AG* (Germany

Genoptix Inc., of Carlsbad, Calif., and HistoRx Inc., of New Haven, Conn., entered a multiyear licensing agreement under which Genoptix gained exclusive commercial laboratory rights in the U.S

terms of the deal were not disclosed (3/16) Inspire Pharmaceuticals Inc. (ISPH) InSite Vision Inc. (AMEX:ISV) Collaboration giving Inspire exclusive rights in the U.S

January | February | March | April | May | June | July | August | September | October | November | December | December - 2010 Company Company Type/Product Area Terms/Details Adimab Inc. Genentech Inc. (NYSE:DNA), Human Genome Sciences Inc. (HGSI) and Eli Lilly and Co. Adimab initiated three new research collaborations for the use of its antibody discovery platform technology Financial terms were not disclosed Advanced Cell Technology Inc. (OTC BB:ACTC) Roslin Cells Ltd

January | February | March | April | May | June | July | August | September | October | November | December | December - 2010 Biotech Company Pharma Company Type/Product Area Terms/Details Adamis Pharmaceuticals Corp. (OTC BB:ADMP) Beximco Pharmaceuticals Ltd. (Bangladesh) Partnership to introduce four separate drugs in the area of allergy and asthma in the U.S. over three years The two companies also will co-develop other drugs Anaphore Inc. Mitsubishi Tanabe Pharma Corp

ZymoGenetics regains full promotion rights in the U.S

Incyte has all rights in the U.S., and Novartis will develop and commercialize it for hematology-oncology indications outside the country

In addition, Forest gains co-development and full commercialization rights in the U.S